Quarterly ResultJul 22, 2026, 01:46 PM
Dr. Reddy's Q1FY27 Revenue ₹80.7B, Profit ₹4.4B; Semaglutide Impact
AI Summary
Dr. Reddy's Laboratories reported Q1FY27 consolidated revenues of ₹80,705 million, a 5.6% decrease year-over-year but a 7.4% increase quarter-over-quarter. Profit after tax attributable to equity holders was ₹4,435 million, down 69% YoY but up 102% QoQ, significantly impacted by a ₹2,397 million provision for semaglutide API-related costs. The company also appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and M/s Deloitte Haskins & Sells, LLP as its Independent Registered Public Accounting Firm.
Key Highlights
- Q1FY27 consolidated revenues were ₹80,705 million, down 5.6% year-over-year.
- Profit after tax attributable to equity holders was ₹4,435 million, a 69% decrease YoY.
- Diluted EPS for Q1FY27 was ₹5.32, representing a 69% decrease YoY.
- Results include a ₹2,397 million provision for semaglutide API-related costs.
- North America revenue decreased 35% YoY to ₹22,048 million.
- Emerging Markets revenue grew 31% YoY to ₹18,328 million.
- Dr. Sridevi Khambhampaty was appointed Global Head of Biologics and Senior Management Personnel.
- M/s Deloitte Haskins & Sells, LLP was appointed as the Independent Registered Public Accounting Firm.
Price Impact
More from RDY